Alzheimer's Disease (AD)
Alzheimer's disease is the most common form of dementia, characterized by amyloid plaques, tau tangles, synaptic loss, and brain atrophy. It leads to progressive memory loss, cognitive decline, and functional dependence. Early detection allows for planning, risk reduction, and access to emerging therapies.
Symptoms by Stage
- Preclinical: asymptomatic; biomarker changes (amyloid PET, CSF)
- Mild Cognitive Impairment (MCI) due to AD: mild memory/language deficits; daily function intact
- Mild AD: short-term memory loss, word-finding difficulty, trouble managing finances
- Moderate AD: disorientation, personality changes, wandering, impaired ADLs
- Severe AD: loss of communication, incontinence, dysphagia, total dependence
Diagnosis
- Detailed history (patient + caregiver), cognitive testing (MoCA, MMSE)
- Functional assessment (ADLs/IADLs)
- Labs to rule out reversible causes (thyroid, B12, syphilis, HIV)
- Structural imaging (MRI/CT) to assess atrophy, vascular lesions
- Biomarkers: amyloid PET, tau PET, CSF Aβ42/tau, plasma phosphorylated tau assays
- Genetic testing (APOE, autosomal dominant genes) in select cases
Treatment & Management
Medications
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild-moderate AD
- Memantine (NMDA antagonist) for moderate-severe AD
- Disease-modifying monoclonal antibodies (lecanemab, donanemab) for early symptomatic patients with confirmed amyloid pathology—require MRI monitoring for ARIA
- Treat comorbid depression/anxiety (SSRIs), psychosis (low-dose atypical antipsychotics when necessary)
Lifestyle & Cognitive Support
- Cognitive stimulation, structured routines, memory aids
- Physical activity, Mediterranean/MIND diet, sleep optimization
- Manage cardiovascular risk factors (BP, lipids, diabetes)
- Home safety evaluation; driving assessment
- Caregiver education, respite care, support groups
Advance Planning
- Discuss goals of care, legal/financial planning, power of attorney
- Plan for progressive care needs (home health, adult day programs, long-term care)
Living with Alzheimer's
- Keep a daily schedule; label items, use calendars/reminders
- Encourage purposeful activities (music, art, gardening)
- Monitor for weight loss or swallowing difficulties; consider speech therapy
- Manage behavioral symptoms with non-pharmacologic approaches first (redirect, reassure)
Complications
- Malnutrition, dehydration
- Falls, fractures
- Infections (pneumonia, UTIs)
- Caregiver stress, burnout, depression
Research & Future Directions
Areas include anti-tau therapies, neuroinflammation modulation, regenerative medicine, and digital diagnostics (eye tracking, speech analysis).
Experimental & Emerging Treatments
- Anti-Tau Therapies: Monoclonal antibodies and antisense oligonucleotides target tau aggregation/spread.
- Neuroinflammation Modulators: Microglial-targeted drugs (CSF1R inhibitors) aim to balance protective vs harmful immune responses.
- Stem Cell & Gene Therapies: Investigated for neuronal replacement and APOE modification.
- Digital Biomarkers & AI: Continuous speech, gait, and wearables detect subtle changes earlier than annual clinic visits.
Track Alzheimer's with Diagnoza.care
Plan Ahead with Insight – Log cognition scores, mood, sleep, medications, imaging, caregiver notes, and functional changes; schedule neurology visits, infusion appointments, and caregiver counseling; capture side effects and let the AI companion flag trends prompting reassessment.
Medical Disclaimer: Informational only. Work with your neurologist or memory clinic for diagnostic confirmation, treatment decisions, and care coordination.
Sources: Alzheimer's Association, American Academy of Neurology, National Institute on Aging